Overall Anxiety Severity and Impairment Scale |
OASIS |
Screening |
Assessor administered |
Mini Mental State Examination |
MMSE |
Screening |
Assessor administered |
Structured Clinical Interview for DSM-5 |
SCID-5 |
Screening |
Assessor administered |
Demographics |
N/A |
Baseline |
Self-report |
Pain, Enjoyment, General Activity Scale |
PEG |
Baseline |
Self-report |
Timeline Followback |
TLFB |
Baseline (past 30 days), Weekly (past 7 days), Post-treatment (past 30 days), 2-mo follow-up (past 30 days) |
Self-report |
Urine Drug Screen |
UDS |
Baseline, Post-treatment, 2-mo follow-up |
Biological sample, collected over video call |
Credibility and Expectancy Questionnaire |
CEQ |
Week 2 |
Self-report |
Depression, Anxiety, and Stress Scale |
DASS-21 |
Weekly |
Self-report |
Adverse Events |
N/A |
Weekly |
Self-report |
Anxiety Sensitivity Index |
ASI-3 |
Biweekly |
Self-report |
Pain Catastrophizing Scale |
PCS |
Biweekly |
Self-report |
Treatment Satisfaction Questionnaire |
TSQ |
Post-treatment |
Self-report |
Yale Adherence and Competence Scale |
YACS |
Following treatment completion |
Completed by rater |